GOQii and Acrannolife Genomics Announce GrafCare Program
A Revolutionary AI-Driven Initiative Redefining Post-Transplant Care
GOQii, a leading smart preventive healthcare company, has joined forces with Acrannolife Genomics, a pioneer in precision diagnostics, to launch the GrafCare Program. This ground breaking initiative leverages advanced genomic diagnostics, artificial intelligence (AI), and personalized health monitoring to redefine post-transplant care for organ recipients in India.
Post-transplant care is a critical yet underserved segment in healthcare. To address the unique challenges faced by transplant recipients, the GrafCare Program combines Acrannolife’s patented Trunome test with GOQii’s smart health ecosystem. This powerful integration offers early detection, real-time health monitoring, and tailored support to enhance patient outcomes and quality of life.
Key Features of the GrafCare Program
Early Detection with Trunome Test: Acrannolife’s US-patented Trunome test is a non-invasive blood test that identifies early signs of organ rejection or infection. Powered by advanced genomic research and AI, the test provides clinicians with precise, actionable insights to intervene before complications escalate.
AI-Powered Personalized Health Monitoring: Patients receive a GOQii Smart Vital Device, which tracks vital parameters such as heart rate, blood pressure, and oxygen levels in real time. AI-driven predictive analytics assess patient data to generate early alerts and personalized recommendations, enabling proactive care.
Preventive Care and Expert Coaching: The program provides access to nutritionists and counselors who design customized recovery plans tailored to each patient’s genetic profile and health data. A focus on preventive care helps patients manage long-term health while reducing reliance on reactive interventions.
Financial Accessibility: To make advanced care accessible, the program offers interest-free loans for up to one year, along with discounts on immunosuppressants and free diagnostic tests such as Tacrolimus and kidney/liver function tests.
Advancing Preventive and Predictive Medicine
The GrafCare Program represents a major leap in healthcare innovation, demonstrating the power of AI and genomics to transform post-transplant care. Unlike traditional approaches that react to complications after they occur, GrafCare adopts a proactive and predictive model, anticipating health issues before they arise.
“This is more than a health program; it’s a lifeline for transplant recipients,” said Vishal Gondal, Founder & CEO, GOQii. “With GrafCare, we’re harnessing the power of AI and genomics to empower patients and clinicians alike, offering a new level of care that was previously unattainable,” he added.
"Having personally experienced the transplant journey within my own family, I understand the emotional and physical challenges patients face. The GrafCare Program, powered by our US-patented Trunome test, offers early and accurate detection of organ rejection, giving patients the best chance to protect their graft. Our goal is to provide the highest level of care, so transplant recipients can focus on healing and living a full, healthy life without the added worry of their health or finances." Said Agragesh Ramani, Co-founder, Acrannolife Genomics
A Vision for the Future of Healthcare
With over 20,000 transplants performed annually in India and a growing global demand for post-transplant solutions, the GrafCare Program is poised to redefine healthcare delivery. This initiative reflects the future of precision medicine, where advancements in AI and genomics enable personalized, affordable, and scalable healthcare.
The long-term vision for GrafCare includes expanding into global markets, particularly in Southeast Asia and the Middle East, regions with significant transplant populations. By integrating predictive medicine with real-time monitoring, GrafCare has the potential to improve millions of lives worldwide.